ArticleAlzheimer's & dementia (New York, N. Y.)2019
Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications.
Article in Alzheimer's & dementia (New York, N. Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Late-Onset Depression and Dementia: A Systematic Review of the Temporal Relationships and Predictive Associations.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Pooled it
- Foundational model aided automatic high-throughput drug screening using self-controlled cohort study.medRxiv : the preprint server for health sciences · 2024Article
- Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Antidepressant exposure and long-term dementia risk in a nationwide retrospective study on US veterans with midlife major depressive disorder.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Nucleoside Reverse Transcriptase Inhibitor Exposure Is Associated with Lower Alzheimer's Disease Risk: A Retrospective Cohort Proof-of-Concept Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Identification of risk genes for Alzheimer's disease by gene embedding.Cell genomics · 2022Article
- Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Revealing Unknown Benefits of Existing Medications to Aid the Discovery of New Treatments for Post-Traumatic Stress Disorder.Psychiatric research and clinical practice · 2022Article
- Harnessing the paradoxical phenotypes of APOE ɛ2 and APOE ɛ4 to identify genetic modifiers in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Treatment with TNF-α inhibitors versus methotrexate and the association with dementia and Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Brain cell somatic gene recombination and its phylogenetic foundations.The Journal of biological chemistry · 2020Review
- Data-driven discovery of associations between prescribed drugs and dementia risk: A systematic review.Alzheimer's & dementia (New York, N. Y.)Review
- Anti-epileptic drug use and subsequent degenerative dementia occurrence.Alzheimer's & dementia (New York, N. Y.)Article
- Assessment of cognitive games to improve the quality of life of Parkinson's and Alzheimer's patients.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is a significant need for disease-modifying therapies to treat and prevent dementia, including Alzheimer's disease. Availability of real-world observational information and new analytic techniques to analyze large volumes of data can provide a path to aid drug discovery.
methodsUsing a self-controlled study design, we examined the association between 2181 medications and incidence of dementia across four US insurance claims databases. Medications associated with ≥50% reduction in risk of dementia in ≥2 databases were examined.
resultsA total of 117,015,066 individuals were included in the analysis. Seventeen medications met our threshold criteria for a potential protective effect on dementia and fell into five classes: catecholamine modulators, anticonvulsants, antibiotics/antivirals, anticoagulants, and a miscellaneous group. DISCUSSION: The biological pathways of the medications identified in this analysis may be targets for further research and may aid in discovering novel therapeutic approaches to treat dementia. These data show association not causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.